RT Journal Article
SR Electronic
T1 Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.07.20170241
DO 10.1101/2020.08.07.20170241
A1 Wright, Daniel
A1 Allen, Elizabeth R.
A1 Clark, Madeleine H.A.
A1 Gitonga, John N.
A1 Karanja, Henry K.
A1 Hulswit, Ruben
A1 Taylor, Iona
A1 Biswas, Sumi
A1 Marshall, Jennifer
A1 Mwololo, Damaris
A1 Muriuki, John
A1 Bett, Bernard
A1 Bowden, Thomas A.
A1 Warimwe, George M.
YR 2020
UL http://medrxiv.org/content/early/2020/08/11/2020.08.07.20170241.abstract
AB Rift Valley fever (RVF) is a viral haemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection, and that this correlates with acquisition of virus neutralizing antibodies (nAb) that target the viral envelope glycoproteins. However, naturally acquired immunity to RVF in humans is poorly described. Here, we characterized the immune response to the viral envelope glycoproteins, Gn and Gc, in RVFV-exposed Kenyan adults. Long-lived IgG (dominated by IgG1 subclass) and T cell responses were detected against both Gn and Gc. However, antigen-specific antibody depletion experiments showed that Gn-specific antibodies dominate the RVFV nAb response. IgG avidity against Gn, but not Gc, correlated with nAb titers. These data are consistent with the greater level of immune accessibility of Gn on the viral envelope surface and confirm the importance of Gn as an integral component for RVF vaccine development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported through grants from the Wellcome Trust (grants no. 203077/Z/16/Z and 203141/Z/16/Z), an Oak foundation fellowship to GMW, and by the Medical Research Council (MR/L009528/1m MR/S007555/1, MR/N002091/1 to T.A.B.). This manuscript was submitted for publication with permission from the Director of the Kenya Medical Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was provided by the Kenya Medical Research Institute Scientific and Ethics Review Unit (SSC 3296), and the African Medical Research Foundation's Ethics and Scientific Review Committee (approval number P65-2013).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in this manuscript is not available elsewhere